- BridgeBio Pharma Inc at JPMorgan Healthcare Conference TranscriptJan 08, 2024
- BridgeBio Pharma Inc to Discuss Additional Data from the Phase 3 ATTRibute-CM Study TranscriptNov 12, 2023
- BridgeBio Pharma Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2023
- BridgeBio Pharma Inc ATTRibute-CM Phase 3 TranscriptAug 28, 2023
- BridgeBio Pharma Inc Topline Results TranscriptJul 17, 2023
- BridgeBio Pharma Inc at Bank of America Global Healthcare Conference TranscriptMay 10, 2023
- BridgeBio Pharma Inc BBP-418 Update TranscriptMar 21, 2023
- BridgeBio Pharma Inc at Cowen Health Care Conference TranscriptMar 08, 2023
- BridgeBio Pharma Inc PROPEL2 Update TranscriptMar 06, 2023
- BridgeBio Pharma Inc Roundtable Discussion TranscriptFeb 16, 2023
- BridgeBio Pharma Inc at JPMorgan Healthcare Conference TranscriptJan 09, 2023
- BridgeBio Pharma Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2022
- BridgeBio Pharma Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 15, 2022
- BridgeBio Pharma Inc to Discuss Phase 2b Data and Phase 3 Trial Design for Encaleret in ADH1- Conference Call TranscriptJun 13, 2022
- BridgeBio Pharma Inc at UBS Global Healthcare Conference TranscriptMay 24, 2022
- BridgeBio Pharma Inc at Citi Biopharma Co-Panel Day (Virtual) TranscriptMay 18, 2022
- BridgeBio Pharma Inc at Bank of America Healthcare Conference TranscriptMay 11, 2022
- BridgeBio Pharma Inc to Discuss Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)- Conference Call TranscriptMar 14, 2022
- BridgeBio Pharma Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 10, 2022
- BridgeBio Pharma Inc to Discuss Topline Results from Phase 3 Attribute-CM Study Call TranscriptDec 27, 2021
- BridgeBio Pharma Inc at H C Wainwright Precision Oncology Conference (Virtual) TranscriptOct 20, 2021
- BridgeBio Pharma Inc R&D Day TranscriptOct 12, 2021
- BridgeBio Pharma Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 08, 2021
- BridgeBio Pharma Inc at UBS Global Healthcare Virtual Conference TranscriptMay 25, 2021
- BridgeBio Pharma Inc to Discuss Proof-of-Concept Data for Encaleret in Autosomal Dominant Hypocalcemia Type 1 TranscriptMar 22, 2021
- BridgeBio Pharma Inc Extraordinary Shareholders Meeting TranscriptJan 19, 2021
- BridgeBio Pharma Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 11, 2021
- BridgeBio Pharma Inc and Eidos Therapeutics Inc Announce Merger Agreement - Conference Call TranscriptOct 05, 2020
- BridgeBio Pharma Inc R&D Day TranscriptSep 29, 2020
- BridgeBio Pharma Inc at Citi BioPharma Conference (Virtual)- Panel: TTR Amyloidosis TranscriptSep 09, 2020
- BridgeBio Pharma Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 11, 2020
- BridgeBio Pharma Inc Annual Shareholders Meeting TranscriptJun 02, 2020
- BridgeBio Pharma Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) TranscriptMay 14, 2020
- BridgeBio Pharma Inc and Eidos Therapeutics Inc at Cowen HealthCare Conference TranscriptMar 04, 2020
- BridgeBio Pharma Inc and Eidos Therapeutics Inc at Leerink Global Healthcare Conference TranscriptFeb 25, 2020
- BridgeBio Pharma Inc at Piper Jaffray Healthcare Conference TranscriptDec 03, 2019
BridgeBio Pharma Inc at Goldman Sachs Global Healthcare Conference Transcript
Good afternoon. We'll continue with the next session. I'm Paul Choi, and I cover the SMid Cap Biotechnology sector here at the firm. And it's my pleasure to welcome BridgeBio for this session. From management joining us is Founder and CEO, Neil Kumar. What we'll do is Q&A. If any audience members along the way have any questions for Neil, please feel free to raise your hand, and we'll try and get a mic to you. But maybe before we start with Q&A, Neil, maybe if you want to provide some any high-level comments that you think are of interest. Otherwise, we can just go into Q&A.
Yes, sure. Happy to. First of all, thanks, everyone, for the time. I think our strategy a bit large over the next 18 months or so is informed by 2 inputs, really, number 1 is our continued belief in our late-stage pipeline of Phase II or Phase III assets in $1 billion-plus markets. And we can talk about those, but those are five
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)